Skip to main content

Table 4 The differences of urine NGAL and MMP-9 between the control and CKD subgroups

From: Identification of urine neutrophil gelatinase-associated lipocalin molecular forms and their association with different urinary diseases in cats

Parameter Control
(n = 12)
Stage 2
(n = 25)
Stage 3
(n = 19)
Stage 4
(n = 11)
p
uNGAL (ng/ml) d 0.5 (0.3–0.6) a, b n = 12 0.3 (0.2–0.5) a
n = 23
0.5 (0.3–0.9) b
n = 18
0.6 (0.3–1.2) b
n = 11
0.030*
UNCR (10− 6) d 0.17 (0.1–0.3) a
n = 12
0.17 (0.1–0.5) a
n = 23
0.605 (0.3–1.4) b
n = 18
1.33 (0.9–2.7) c
n = 11
< 0.001**
NGAL Monomer e 0% (0/12) 20% (5/25) 63.2% (12/19) 81.8% (9/11) < 0.001**
NGAL Dimer e 0% (0/12) 20% (5/25) 0% (0/19) 0% (0/11) 0.643
NGAL/MMP-9 e 58.3% (7/12) 60% (15/25) 84.2% (16/19) 90.9% (10/11) 0.102
  1. The different superscripts (a, b, c) indicate various significant differences
  2. dData are medians (IQR) and compared by the Kruskal-Wallis test (p < 0.05 indicated significant difference) and post hoc by Dunn’s test.
  3. eFisher’s exact test are used to compare the category data and presented in%.
  4. uNGAL Urine NGAL, UNCR Urine NGAL-to-creatinine ratio